Shire puts heat on FDA for long-stalled midodrine drugs hearing
This article was originally published in Scrip
After a year of waiting for the US FDA to make a move, Shire on 22 September was apparently getting antsy, issuing a statement that it was at an impasse with regulators about the agency's August 2010 proposal to withdraw approval for ProAmatine (midodrine) and its generic equivalents, with no word on whether the company would finally be granted a public hearing on the matter.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.